Tag: sorafenib

1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events ...

1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable ...

Click to read the study in the European Journal of Cancer. 

1. Sorafenib maintenance therapy following allogenic stem cell transplantation in FLT3-ITD acute myeloid leukemia was associated with significantly lower rates ...

1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate ...

1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate ...

1. Combination treatment of atezolizumab and bevacizumab was shown to significantly increase overall survival and progression-free survival outcomes in patients ...

1. After 2 years of treatment with sorafenib, patients with desmoid tumors had significantly increased progression-free survival rates compared to ...

In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Effect of ...

1. Compared to placebo, treatment with everolimus did not improve survival in patients with advanced hepatocellular carcinoma (HCC) who had ...